|
heart failure |
14 |
|
chinese |
11 |
|
covid-19 |
11 |
|
adult cardiology |
9 |
|
myocarditis |
9 |
|
cardiovascular diseases |
8 |
|
machine learning |
8 |
|
recurrent cardiovascular events |
8 |
|
risk prediction score |
8 |
|
sars-cov-2 |
8 |
|
stem cells |
8 |
|
venous thromboembolism |
8 |
|
adherence |
7 |
|
barriers |
7 |
|
cardiology |
7 |
|
focus group |
7 |
|
hypercholesterolemia |
7 |
|
lipid-lowering agents |
7 |
|
preferences |
7 |
|
stroke |
7 |
|
atrial fibrillation |
6 |
|
coronary artery disease |
6 |
|
general diabetes |
6 |
|
high sensitive troponin level |
6 |
|
statin intolerance |
6 |
|
valvular heart disease |
6 |
|
acute coronary syndrome |
5 |
|
brugada syndrome |
5 |
|
clinical pharmacology |
5 |
|
cohort studies |
5 |
|
coronary heart disease |
5 |
|
coronary intervention |
5 |
|
drug escalation |
5 |
|
electronics |
5 |
|
genetic analysis |
5 |
|
international normalized ratio |
5 |
|
ischaemic heart disease |
5 |
|
long qt syndrome |
5 |
|
mexiletine |
5 |
|
mitral valve |
5 |
|
monomorphic ventricular tachycardia |
5 |
|
mortality |
5 |
|
non-vitamin k oral anticoagulants |
5 |
|
polymorphic ventricular tachycardia |
5 |
|
quinidine |
5 |
|
risk factors |
5 |
|
telemonitoring |
5 |
|
time in therapeutic range |
5 |
|
tricuspid valve insufficiency |
5 |
|
ventricular fibrillation |
5 |
|
warfarin |
5 |
|
deep vein thrombosis |
4 |
|
fluoroscopy |
4 |
|
leadless pacemaker |
4 |
|
pregnancy |
4 |
|
pulmonary embolism |
4 |
|
pulmonary hypertension |
4 |
|
safety |
4 |
|
septal pacing |
4 |
|
technique |
4 |
|
telemedicine |
4 |
|
trend |
4 |
|
tricuspid annuloplasty |
4 |
|
valvular surgery |
4 |
|
apixaban |
3 |
|
border restriction |
3 |
|
cardiac distress inventory |
3 |
|
cardiac rehabilitation |
3 |
|
commodity hardware |
3 |
|
coronavirus disease 2019 (covid-19) |
3 |
|
dementia |
3 |
|
device related thrombus |
3 |
|
ehealth/telemedicine/mobile health |
3 |
|
elemedicine |
3 |
|
epidemiology |
3 |
|
hyponatremia |
3 |
|
infection controlt |
3 |
|
information extraction |
3 |
|
large language models |
3 |
|
left atrial appendage occlusion |
3 |
|
lupus nephritis |
3 |
|
microlife |
3 |
|
mobile app |
3 |
|
neurology |
3 |
|
offline |
3 |
|
outcomes |
3 |
|
photoplethysmography |
3 |
|
premature ventricular beats |
3 |
|
prompt strategy |
3 |
|
psychometrics |
3 |
|
reliability |
3 |
|
renal biopsy reports |
3 |
|
resilience |
3 |
|
screening |
3 |
|
smartphone |
3 |
|
sodium |
3 |
|
susceptible exposed infectious recovered (seir) model |
3 |
|
validity |
3 |
|
virology |
3 |
|
atrial tachycardia |
2 |
|
drug discovery |
2 |
|
electrocardiogram |
2 |
|
gene therapy |
2 |
|
guillain barre syndrome |
2 |
|
left bundle branch pacing |
2 |
|
pancreatitis |
2 |
|
stem cell |
2 |
|
adult-onset still's disease (aosd) |
1 |
|
aortic valve stenosis |
1 |
|
autoimmune disease |
1 |
|
autoimmunity |
1 |
|
cancer |
1 |
|
cardiac intervention |
1 |
|
echocardiography |
1 |
|
heart valve prosthesis |
1 |
|
immune checkpoint inhibitor |
1 |
|
immunotherapy |
1 |
|
leukocyte |
1 |
|
mitral regurgitation |
1 |
|
mitral valve (mv) repair |
1 |
|
mrna vaccine |
1 |
|
transcatheter aortic valve replacement |
1 |
|
transgenic mice |
1 |
|
vaccine |
1 |
